Investment in early translational cancer research
New report is the first to look at government and charitable funding of translational research
March 18, 2011
Knowledge of how to translate cancer research into practical application helps to ensure that research discoveries benefit patients as quickly as possible. The Canadian Cancer Research Survey (CCRS), conducted annually by the Canadian Cancer Research Alliance, was used to analyze and report on investments in “early translational” cancer research, which moves fundamental discoveries to early-stage clinical trials.
The comprehensive classification framework adopted for the study was originally developed by the U.S. National Cancer Institute’s Translational Research Working Group and categorizes research by specific diagnostics and treatment/interventions (modalities), as well as developmental phases.
Between 2005 and 2007, early translational cancer research comprised 27% ($102 million per year) of the overall cancer research investment made by the 37 programs/organizations that participated in the CCRS. Research on drugs – including biologics, small molecules, and immune response modifiers – made up over 50% of the investment.
While federal government organizations were key funders of cancer research overall, strategic investments by Genome Canada and its provincial partners, as well as the Ontario Institute for Cancer Research, made significant contributions to early translational cancer research.
The survey report, Investment in Early Translational Cancer Research, provides detailed tables and figures on various aspects of Canada’s investment in this important field. If you have any questions about the report, please email Kim Badovinac.